EndedDecember 31,Nine Months EndedSeptember 30,20072008200920092010(unaudited)(in thousands, except per share data)Statement of operations data:Revenue$11,034$19,660$20,719$14,683$32,725Operating expenses:Research and development29,24841,82151,79238,32668,867General and administrative6,5029,16410,1207,50410,199Total operating expenses35,75050,98561,91245,83079,066Loss from operations(24,716)(31,325)(41,193)(31,147)(46,341)Other income and expense:Other income (expense), net—18(333)(273)722Loss on loan extinguishment—(248)——(582)Interest expense(2,437)(2,086)(2,811)(2,141)(2,361)Interest income2,1711,16814412187Other income (expense), net(266)(1,148)(3,000)(2,293)(2,134)Net loss before taxes(24,982)(32,473)(44,193)(33,440)(48,475)Tax benefit——10063—Net loss$(24,982)$(32,473)$(44,093)$(33,377)$(48,475)Net loss per share applicable to common stockholders-basic and diluted$(17.89)$(21.08)$(27.43)$(20.87)$(2.13)Weighted average number of common shares used in net loss per share calculation-basic and diluted1,3961,5411,6071,59922,7735Table of ContentsAs of September 30, 2010(unaudited, in thousands)Balance Sheet Data:Cash, cash equivalents, and marketable securities$87,022Working capital57,325Total assets96,512Loans payable, including current portion, net of discount23,140Accumulated deficit(226,200)Total stockholders’ equity23,4116Table of ContentsRISK FACTORSInvesting in our common stock involves a high degree of risk.
risks actually occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our common stock could decline and you could lose all or part of your investment.Risks Related to Development, Clinical Testing and Regulatory Approval of Our Drug CandidatesWe are dependent on the success of our lead drug candidate, tivozanib, which is in phase 3 development.To date, we have invested a significant portion of our efforts and financial resources in the research and development of tivozanib.
tivozanib’s safety and efficacy through current and future clinical trials;•the prevalence and severity of adverse side effects;•timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;•achieving and maintaining compliance with all regulatory requirements applicable to tivozanib;•the availability, relative cost and relative efficacy of alternative and competing treatments;•the effectiveness of our own or our potential strategic partners’ marketing, sales and distribution strategy and operations;•the ability of our third-party manufacturers to manufacture clinical trial supplies of tivozanib and to develop, validate and maintain a commercially
viable manufacturing process that is compliant with current good manufacturing practices, or cGMP;•our ability to successfully launch commercial sales of tivozanib, assuming FDA approval is obtained, whether alone or in collaboration with others;•our ability to avoid third party patent interference or patent infringement claims;•acceptance of tivozanib as safe and effective by patients, the medical community and third-party payors; and•a continued acceptable safety profile of the product following approval.7Table of ContentsMany of these factors are beyond our control.
will not be able to obtain regulatory approval for such product candidate, and the resulting delays in developing other product candidates and conducting related preclinical studies and clinical trials, as well as the potential need for additional
successful in discovering, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.Although a substantial amount of our efforts will focus on the continued clinical testing and potential approval of tivozanib as well as
obtaining regulatory approval or commercializing product candidates on a timely basis, or at all, which would require us to incur additional costs and delay receipt of any product revenue.We cannot predict whether we will encounter problems with any of our ongoing or planned clinical trials that will cause us or regulatory
clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates.We believe that our existing cash and cash equivalents (including the proceeds received from our sale of common stock in November 2010),
market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.Our future capital requirements depend on many factors, including:•the number and characteristics of the product candidates we pursue;•the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials;•the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;•the cost of commercialization activities if any of our product candidates are approved for sale, including marketing, sales and distribution costs;12Table of Contents•the cost of manufacturing our product candidates and any products we successfully commercialize;•our ability to establish and maintain strategic partnerships, licensing or other arrangements and the financial terms of such agreements;•the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of
limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.A substantial portion of our future revenues may be dependent upon our agreements with OSI Pharmaceuticals and Biogen Idec.Our success will depend in significant part on our ability to attract and maintain strategic partners and strategic relationships to
For example, to execute our business plan, we will need to successfully:•execute product development activities;•obtain required regulatory approvals for the development and commercialization of our product candidates;•build and maintain a strong intellectual property portfolio;•build and maintain robust sales, distribution and marketing capabilities;•gain market acceptance for our products;•develop and maintain successful strategic relationships; and•manage our spending as costs and expenses increase due to clinical trials, regulatory approvals and commercialization.If we are unsuccessful in accomplishing these objectives, we may not be able to develop product candidates, raise capital, expand our
are not able to compete effectively against our current and future competitors, our business will not grow and our financial condition and operations will suffer.If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize our
Regardless of the merits or eventual outcome, liability claims may result in:•decreased demand for our product candidates or products that we may develop;•injury to our reputation;•withdrawal of clinical trial participants;•costs to defend the related litigation;•diversion of management’s time and our resources;•substantial monetary awards to trial participants or patients;•product recalls, withdrawals or labeling, marketing or promotional restrictions;•loss of revenue;•the inability to commercialize our product candidates; and•a decline in our stock price.17Table of ContentsOur inability to obtain and retain sufficient product liability insurance at an acceptable
Market acceptance of any products for which we receive approval depends on a number of factors, including:•the efficacy and safety of the product candidate, as demonstrated in clinical trials;18Table of Contents•the clinical indications for which the drug is approved;•acceptance by physicians, major operators of cancer clinics and patients of the drug as a safe and effective treatment;•with respect to tivozanib, the results obtained in our phase 3 clinical trial for the treatment of advanced clear cell RCC and the extent to which the
this prospectus include, among other things, statements about:•our plans to develop and commercialize tivozanib, AV-299 and our other product candidates;•our ongoing and planned preclinical studies and clinical trials;•the potential benefits of strategic partnership agreements and our ability to enter into selective strategic partnership arrangements;•the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;•the rate and degree of market acceptance and clinical utility of our products;•our plans to leverage our Human Response Platform to discover and develop product candidates;•our ability to quickly and efficiently identify and develop product candidates;•our commercialization, marketing and manufacturing capabilities and strategy;•our intellectual property position;•our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and•other risks and uncertainties, including those listed under the caption “Risk Factors.”We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place